Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies (Q84965417)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

Lia Gore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

E Rivera

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

M Basche

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S L Moulder-Thompson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J Li

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Eppers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Grolnic

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C O'Bryant

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

D Cleere

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Y A Elsayed

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S G Eckhardt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

20 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1942-1949

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21931969%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

13 February 2020

cites work

1 reference

12 December 2020

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

1 reference

12 December 2020

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

1 reference

12 December 2020

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives

1 reference

12 December 2020

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

1 reference

12 December 2020

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

12 December 2020

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

1 reference

12 December 2020

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

1 reference

12 December 2020

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

12 December 2020

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

1 reference

12 December 2020

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

1 reference

12 December 2020

Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.

1 reference

12 December 2020

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

1 reference

12 December 2020

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

1 reference

12 December 2020

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies

1 reference

12 December 2020

Trabectedin therapy for sarcomas.

1 reference

12 December 2020

Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution

1 reference

12 December 2020

Marine metabolites overcoming or circumventing multidrug resistance mediated by ATP-dependent transporters: a new hope for patient with tumors resistant to conventional chemotherapy

1 reference

12 December 2020

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

12 December 2020

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

1 reference

12 December 2020

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

12 December 2020

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

1 reference

12 December 2020

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

12 December 2020

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

12 December 2020

Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts

1 reference

12 December 2020

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

12 December 2020

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

1 reference

12 December 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

12 December 2020

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

12 December 2020

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies

1 reference

12 December 2020

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

1 reference

12 December 2020

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

1 reference

12 December 2020

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

12 December 2020

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

12 December 2020

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

1 reference

12 December 2020

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

12 December 2020

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells

1 reference

12 December 2020